|
OJI Yuusuke
|
Organization 【 display / non-display 】
-
1997.04.01 - 2003.03.31, Faculty of Medicine, Research Assistant
-
2003.04.01 - 2004.03.31, Division of Health Sciences, Graduate School of Medicine, Research Assistant
-
2004.04.01 - 2007.03.31, Division of Health Sciences, Graduate School of Medicine, Associate Professor
-
2007.04.01 - 2009.03.31, Division of Health Sciences, Graduate School of Medicine, Associate Professor
-
2009.04.01 - 2010.09.30, Graduate School of Medicine, Professor
-
2010.10.01 - 2017.03.31, Division of Health Sciences, Graduate School of Medicine, Professor
-
2017.04.01 - , Division of Health Sciences, Graduate School of Medicine, Professor
Education 【 display / non-display 】
Osaka University Faculty of Medicine Graduated | M.D. | 1990.03 |
Osaka University Faculty of Medicine Graduated | 1994.06 |
Employment Record 【 display / non-display 】
Osaka University Graduate School of Medicine Associate Professor | 2004.04 - |
Research topics 【 display / non-display 】
-
Tumor Biology
-
Cancer immunology
Academic Papers 【 display / non-display 】
-
Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.. , Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H., Medicine (Baltimore), 2019 Aug;98(33):e16771. 1., 2019.08, Papers
-
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia., Nakata J, Oji Y, Oka Y, Sugiyama H., Expert Rev Hematol,12: 211-213, 2019, 2019.04, Papers
-
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia, Nakata J, Oji Y, Oka Y, Sugiyama H, Expert Review of Hematology,12(4) 211-213, 2019.04, Papers
-
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma, Tsuboi A. , et al., Cancer Immunology, Immunotherapy,68(2) 331-340, 2019.02, Papers
-
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. , Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H. , Cancer Immunol Immunother., 2018.11, Papers